Compare ALLO & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLO | TKNO |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 236.6M |
| IPO Year | 2018 | 2021 |
| Metric | ALLO | TKNO |
|---|---|---|
| Price | $1.50 | $4.80 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 135.2K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $39,801,000.00 |
| Revenue This Year | N/A | $8.79 |
| Revenue Next Year | $100.00 | $10.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.50 |
| 52 Week Low | $0.86 | $3.94 |
| 52 Week High | $3.78 | $10.37 |
| Indicator | ALLO | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 61.26 | 51.98 |
| Support Level | $1.39 | $4.53 |
| Resistance Level | $1.52 | $4.87 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 87.50 | 91.55 |
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.